Delivery Order SPE2DB22D9353-SPE2DB25FX2FM
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $1,644.72 to DMS Pharmaceutical Group Inc. on September 26, 2025, for the supply of Tissueblue 0.025% syringes in 0.5mL quantities. This delivery order, with an ultimate completion date of October 20, 2025, was issued under a firm fixed-price contract structure without set-aside designation. The work will be performed at DMS Pharmaceutical Group's location in Park Ridge, Illinois. DMS Pharmaceutical Group Inc., a woman-owned small...
- The U.S. Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order contract valued at $3,210.96 to DMS Pharmaceutical Group Inc., a woman-owned small business based in Park Ridge, Illinois. The contract is for the delivery of TISSUEBLUE 0.025% SYRINGE 0.5ML, a specialized pharmaceutical product, with a period of performance through December 20, 2024. This award is part of a larger $499,999,999 Indefinite Delivery Contract (IDC) held by DMS Pharmaceutical Group with the DLA under...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business based in Park Ridge, Illinois. The $4,963.32 firm fixed-price delivery order is for the supply of TISSUEBLUE 0.025% SYRINGE 0.5ML medical products. The contract has an ultimate completion date of June 10, 2025. DMS Pharmaceutical Group Inc. holds a $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, which enables the agency...
- On August 19, 2025, the Defense Logistics Agency (DLA) awarded a delivery order valued at $1,654.44 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The delivery order is for TissueBlue 0.025% syringes in 0.5mL quantities, with an ultimate completion date of September 10, 2025. This award utilizes a firm fixed-price contract structure with no set-aside designation, and performance will take place at the contractor's...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a firm fixed-price delivery order valued at $1,654.44 by the Defense Logistics Agency on July 16, 2025, for the supply of TissueBlue 0.025% syringes in 0.5mL quantities. The contract carries an ultimate completion date of August 6, 2025, and was performed at the awardee's location in Park Ridge, Illinois. This delivery order was issued without set-aside designation,...
- The U.S. Defense Logistics Agency (DLA) awarded a firm-fixed-price delivery order contract valued at $4,013.70 to DMS Pharmaceutical Group Inc., a woman-owned small business based in Park Ridge, Illinois. The contract is for the delivery of 0.5 mL syringes containing 0.025% Tissue Blue solution. This order is issued against DMS Pharmaceutical's indefinite delivery contract SPE2DB valued at up to $4,999,999 through 2025, which enables DLA to procure a broad range of pharmaceutical products for...
- On August 18, 2025, the Defense Logistics Agency, operating under the Medical Supply Chain division, awarded a delivery order valued at $1,654.44 to DMS Pharmaceutical Group Inc. for TISSUEBLUE 0.025% Syringe 0.5ML. This firm fixed-price delivery order, with an ultimate completion date of September 9, 2025, was issued without a set-aside designation. DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, will perform the...
- The Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order contract to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract, valued at $4,136.10, is for the supply of a specific pharmaceutical product - TISSUEBLUE 0.025% SYRINGE 0.5ML. This delivery order is part of a larger $499,999,999 Indefinite Delivery Contract (IDC) held by DMS Pharmaceutical Group with the DLA under the SPE2DB program. The IDC...
- This federal contract award, valued at $1,654.44, was issued by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business. The contract is for the delivery of TISSUEBLUE 0.025% SYRINGE 0.5ML, a medical product, with an ultimate completion date of August 6, 2025. The contract is a firm fixed-price delivery order, and there was no set-aside used. DMS Pharmaceutical Group Inc. is a pharmaceutical wholesaler based in Park Ridge, Illinois, that specializes in...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a firm fixed-price delivery order valued at $4,136.10 by the Defense Logistics Agency (DLA) on August 25, 2025. The contract calls for delivery of TissueBlue 0.025% Syringe 0.5ML, a pharmaceutical product to be delivered to Park Ridge, Illinois, with an ultimate completion date of September 16, 2025. This delivery order was issued without a set-aside designation,...
- SPE2DB22D9353Indefinite Delivery Contract
- SPE2DB22D9353-SPE2DB25FX2FMDelivery Order
The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,654.44 to DMS Pharmaceutical Group Inc. on September 26, 2025, for the supply of Tissueblue 0.025% syringes in 0.5ml quantities. This firm fixed-price delivery order is scheduled for ultimate completion by October 20, 2025, with fulfillment from the vendor's location in Park Ridge, Illinois. The award did not utilize a set-aside designation, allowing DMS Pharmaceutical Group to compete on an unrestricted basis despite its status as a woman-owned small business. DMS Pharmaceutical Group Inc. is a woman-owned small business pharmaceutical wholesaler that has served as a critical supplier within the federal pharmaceutical supply chain since its SAM.gov registration in 2001. This delivery order is issued under the company's larger Indefinite Delivery Contract with the DLA under the SPE2DB program, valued at $499.999 billion and valid through November 2026. This overarching IDC enables the DLA to procure a comprehensive range of pharmaceutical products, branded and generic prescription drugs, biologics, and medical consumables to support Department of Defense healthcare facilities worldwide. DMS Pharmaceutical Group's extensive federal contract portfolio demonstrates its consistent ability to deliver specialized pharmaceutical items, including oncology treatments, vaccines, and other medical supplies essential to military health operations.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.7k | 9/26/25 |